Publicacions

Martinez-Campos E, Robles MA, Horno R, Meza R, Sánchez S, Castilló J, Vidal-Jordana A, Zabalza A, Rodríguez-Acevedo B, Vilaseca A, Arrambide G, Pappolla A, Midaglia L, Galán I, Ariño H, Carvajal R, Mongay N, Cobo-Calvo Á, Comabella M, Tur C, Sastre-Garriga J, Tintoré M, Montalban X, Río J. "Effectiveness and associated factors of response to Fampridine in multiple sclerosis: A prospective observational study from an expert center". Mult Scler Relat Disord. 2025 Nov 20. PMID: 41319597

Eixarch H, Boutitah-Benyaich I, Plaza J, Rodríguez-Vidal S, Salvadó M, Mancera-Arteu M, Almenara-Fuentes L, Dalmases M, Vives-Pi M, Montalban X, Barneda-Zahonero B, Espejo C. Reprogramming autoimmunity: inducing antigen-specific tolerance via apoptotic mimicry in an experimental model of multiple sclerosis. J Neuroinflammation. 2025 Nov 28. PMID: 41316372

Capdevila-Bayo M, Rossi R, de Rojas I, Puerta R, Guzmán L, Carrasco M, Muñoz-Morales Á, Olivé C, Montrreal L, García-González P, Bayón-Buján P, Miguel-Romero A, Calm B, Sotolongo-Grau O, Orellana A, Tatinya N, Martínez M, Alegret M, Sanz-Cartagena P, Fernández MV, Marquié M, Valero S, Montalbán X, Camins A, Ramírez A, Martí M, Pividori MI, Boada M, Ruiz A, Ettcheto M, Cano A. A peripheral proteomic signature of Alzheimer's disease is identified in the plasma extracellular vesicles of mild cognitive impairment patients from a memory clinic: the BIOPEXAL study. Res Sq. 2025 Nov 1. PMID: 41282153

Cárdenas-Robledo S, Otero-Romero S, García JD, López N, Carbonell-Mirabent P, Rodríguez M, Guío-Sánchez C, Carvajal R, Passarell-Bacradit MA, Sastre-Garriga J, Montalban X, Tintoré M. Clusters of Comorbidities in Multiple Sclerosis and Their Influence on Healthcare Resource Usage. Eur J Neurol. 2025 Nov. PMID: 41190618

Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Krakovich A, Cheng CY, Riolo JV, Pachai C, Thorpe A, DeBoer E, Kappos L, Cohen JA, Cree BA. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial. Mult Scler. 2025 Nov. PMID: 41190505

Ziemssen T, Freedman MS, Bar-Or A, Montalban X, Teunissen CE, Häring DA, Kukkaro P, Merschhemke M, Kieseier BC, Karnik-Henry M, Gee M, Lange S, Merabet E, Chitnis T, Bittner S, Wiendl H, Hauser SL. Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis. Mult Scler. 2025 Nov. PMID: 41159484

Ajdinaj P, Mongay-Ochoa N, Alberich M, Tintore M, Montalban X, Rovira À, Pareto D, Sastre-Garriga J. Long-term impact of spinal cord reserve on disability accumulation in multiple sclerosis. Mult Scler. 2025 Oct. PMID: 41055560

Boutitah-Benyaich I, Eixarch H, Villacieros-Álvarez J, Hervera A, Cobo-Calvo Á, Montalban X, Espejo C. Multiple sclerosis: molecular pathogenesis and therapeutic intervention. Signal Transduct Target Ther. 2025 Oct 2. PMID: 41034190

Saidha S, Green AJ, Leocani L, Vidal-Jordana A, Kenney RC, Bsteh G, Outteryck O, Thompson A, Montalban X, Coetzee T, Petzold A, Paul F, Balcer LJ, Calabresi PA. The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurol. 2025 Oct. PMID: 40975103

Barkhof F, Reich DS, Oh J, Rocca MA, Li DKB, Sati P, Azevedo CJ, Bagnato F, Calabresi PA, Ciccarelli O, Dwyer MG, DeLuca GC, De Stefano N, Enzinger C, Filippi M, Granziera C, Halper J, Henry RG, Gasperini C, Gauthier S, Kappos L, Laule C, Newsome SD, Montalban X, Morrow SA, Schoonheim MM, Sicotte N, Toosy A, Wilken J, Yousry T, Sastre-Garriga J, Traboulsee A, Ontaneda D, Rovira À, Magnetic Resonance Imaging Network in Multiple Sclerosis, Consortium of Multiple Sclerosis Centers, North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis. Lancet Neurol. 2025 Oct. PMID: 40975102

Montalban X, Lebrun-Frénay C, Oh J, Arrambide G, Moccia M, Pia Amato M, Amezcua L, Banwell B, Bar-Or A, Barkhof F, Butzkueven H, Ciccarelli O, Chataway J, Cohen JA, Comi G, Correale J, Deisenhammer F, Filippi M, Fiol J, Freedman MS, Fujihara K, Granziera C, Green AJ, Hartung HP, Hellwig K, Kappos L, Kimbrough D, Killestein J, Lublin F, Marignier R, Ann Marrie R, Miller A, Otero-Romero S, Ontaneda D, Ramanathan S, Reich D, Rocca MA, Rovira À, Saidha S, Salter A, Sastre-Garriga J, Saylor D, Solomon AJ, Sormani MP, Stankoff B, Tintore M, Tremlett H, Van der Walt A, Viswanathan S, Wiendl H, Wildemann B, Yamout B, Zaratin P, Calabresi PA, Coetzee T, Thompson AJ. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025 Oct. PMID: 40975101

Deisenhammer F, Hegen H, Arrambide G, Banwell BL, Coetzee T, Gnanapavan S, Montalban X, Tumani H, Willrich MA, Freedman MS. Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis. EBioMedicine. 2025 Oct. PMID: 40967951

Pappolla A, Arrambide G, Montalban X. A paradigm shift away from dissemination in time in multiple sclerosis. Nat Rev Neurol. 2025 Dec. PMID: 40962994

Tseriotis VS, Arrambide G, Carnero Contentti E, Tur C, Wattjes MP, Cortese R, Mitsikostas DD, Grigoriadis N, Adamou A, Chlorogiannis DD, Beltsios E, Magyari M, Truelsen TC, Leocani L, Montalban X. MRI lesion distribution criteria for MS, NMOSD and MOGAD differentiation: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2025 Aug 31. PMID: 40889881

Rodero-Romero A, Fernández-Velasco JI, Monreal E, Sainz-Amo R, Álvarez-Lafuente R, Comabella M, Ramió-Torrentà L, García-Domínguez JM, Villarrubia N, Sainz de la Maza S, Domínguez-Mozo M, Quiroga-Varela A, Chico-García JL, Rodriguez-Jorge F, Veiga-Gonzalez JL, Roldán-Santiago E, Espiño M, Rodríguez-Martín E, Álvarez G, Masjuan J, Montalban X, Costa-Frossard L, Villar LM. Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosis. Front Immunol. 2025. PMID: 40852725

Ganjgahi H, Häring DA, Aarden P, Graham G, Sun Y, Gardiner S, Su W, Berge C, Bischof A, Fisher E, Gaetano L, Thoma SP, Kieseier BC, Nichols TE, Thompson AJ, Montalban X, Lublin FD, Kappos L, Arnold DL, Bermel RA, Wiendl H, Holmes CC. AI-driven reclassification of multiple sclerosis progression. Nat Med. 2025 Oct. PMID: 40835969

Vilaseca A, Ariño H, Iacoboni G, Feijóo S, Zabalza A, Fissolo N, Arévalo MJ, Carpio C, Sánchez M, Tintoré M, Comabella M, Montalban X, Barba P, Vidal-Jordana Á. Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy. Eur J Neurol. 2025 Aug. PMID: 40765152

Schmierer K, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Sellebjerg F, Vermersch P, Jin H, Sponton L, Chudecka A, Gardner L, De Stefano N. Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study. Ther Adv Neurol Disord. 2025. PMID: 40756532

Monreal E, Fernández-Velasco JI, Sainz de la Maza S, Espiño M, Villarrubia N, Roldán-Santiago E, Aladro Y, Cuello JP, Ayuso-Peralta L, Rodero-Romero A, Chico-García JL, Rodríguez-Jorge F, Quiroga-Varela A, Rodríguez-Martín E, Pilo de la Fuente B, Martín-Ávila G, Martínez-Ginés ML, García-Domínguez JM, Rubio L, Llufriu S, Comabella M, Montalban X, Álvarez-Bravo G, Veiga-González JL, Masjuan J, Costa-Frossard L, Villar LM. Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis. Int J Mol Sci. 2025 Jul 18. PMID: 40725145

van der Walt A, Strijbis EMM, Bridge F, Coetzee T, Graves J, Brownlee WJ, Butzkueven H, Marrie RA, Hua LH, Lampe A, Tintore M, Montalban X, Calabresi PA, Barkhof F, International Advisory Committee Clinical Trials in MS Workshop on Ageing and MS members. Advancing multiple sclerosis management in older adults. Nat Rev Neurol. 2025 Aug. PMID: 40702382

Kappos L, Burcklen M, D'Ambrosio D, Fox RJ, Freedman MS, Havrdova EK, Hennessy B, Hohlfeld R, Larbalestier A, Lemle A, Lindenstrøm E, Lublin F, Montalban X, Sidorenko T, Sprenger T, Vaclavkova A, Wuerfel J, Pozzilli C. Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial. Mult Scler Relat Disord. 2025 Oct. PMID: 40700861

Cohen JA, Arnold DL, DeLuca J, Hartung HP, Kappos L, Comi G, Selmaj K, Steinman L, Bar-Or A, Montalban X, Havrdová EK, Sheffield JK, Pachai C, Cheng CY, Riolo JV, Cree BA. Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials. Mult Scler. 2025 Sep. PMID: 40698614

Cortese M, Peng X, Edan G, Freedman MS, Hartung HP, Montalban X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Kappos L, Ascherio A, Bjornevik K, BENEFIT Study Group. Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression. Neurology. 2025 Aug 12. PMID: 40674673

Vilaseca A, Urcelay E, Malhotra S, Castillo M, Aroca M, Vidal-Jordana A, Pappolla A, Carvajal R, Arrambide G, González-Jiménez A, Gómez-Delgado I, Cobo-Calvo A, Mongay-Ochoa N, Rodriguez-Acevedo B, Tur C, Villacieros-Álvarez J, Ariño H, Castilló J, Zabalza A, Midaglia L, La Puma D, Sastre-Garriga J, Tintoré M, Río J, Montalban X, Comabella M. The Variant rs7665090 Is Associated With Interferon-Beta Response in Multiple Sclerosis Patients. Eur J Neurol. 2025 Jul. PMID: 40665510

Coll L, Pareto D, Aparicio-Serrano F, Otero-Romero S, Cobo-Calvo A, Reinders E, Alberich M, Arévalo MJ, Arrambide G, Auger C, Castilló J, Comabella M, Galán I, Midaglia L, Nos C, Novak F, Oliver A, Río J, Rodríguez-Acevedo B, Sastre-Garriga J, Vidal-Jordana Á, Zabalza A, Montalban X, Rovira À, Tintoré M, Lladó X, Tur C. Deep learning to predict progression independent of relapse activity at a first demyelinating event. Brain Commun. 2025. PMID: 40620473

Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L, De Stefano N. Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study. Neurol Ther. 2025 Oct. PMID: 40614039

Villacieros-Álvarez J, Sepulveda M, Valls-Carbó A, Fissolo N, Dinoto A, Fernández V, Vilaseca A, Arrambide G, Gutierrez L, Castillo M, Bollo L, Espejo C, Llufriu S, Blanco Y, Armangue T, Álvarez Bravo G, Quiroga-Varela A, Ramió Torrentà L, Cobo-Calvo A, Tintore M, Lünemann JD, Saiz A, Mariotto S, Montalban X, Comabella M. Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm. 2025 Sep. PMID: 40587836

Abdelhak A, Bachhuber F, Ning K, Benkert P, John Boscardin W, Maleska Maceski A, Schaedelin S, Achtnichts L, Finkener S, Lalive PH, Uginet M, Pot C, Du Pasquier R, Hoepner R, Chan A, Gobbi C, Zecca C, Müller S, Roth P, Granziera C, Chitnis T, Madill E, Weiner HL, Green AJ, Hauser SL, Cree BA, Kümpfel T, Havla J, Skripuletz T, Gingele S, Senel M, Vardakas I, Taranu D, Ziemann U, Kowarik MC, Kleiter I, Hoshi MM, Zettl UK, Haarmann A, Thebault S, Freedman MS, Bergman HP, Iacobaeus E, Khademi M, Ferraro D, Cardi M, Mariotto S, Comabella M, Montalban X, Vilaseca-Jolonch A, Strijbis EM, Wessels MH, Killestein J, Hemmer B, Held F, Sellebjerg F, Højsgaard Chow H, Alvarez-Lafuente R, Domínguez-Mozo MI, Hegen H, Berek K, Deisenhammer F, Thouvenot E, Agherbi H, Rejdak K, Gąsior M, Tzanetakos D, Tzartos JS, Sormani MP, Dujmovic Basuroski I, Arrambide G, Khalil M, Piehl F, Teunissen CE, Kuhle J, Tumani H. Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis. J Neurol Neurosurg Psychiatry. 2025 Oct 15. PMID: 40506119

Fissolo N, Schaedelin S, Villar LM, Lünemann JD, Correale J, Rejdak K, Schwab N, Vilaseca A, Held F, García-Merino A, Bittner S, Trojano M, Furlan R, Tumani H, Pérez-Miralles F, Rosenstein I, Galimberti D, Álvarez-Bravo G, Thouvenot E, Llufriu S, Khoury SJ, Hoepner R, Martínez-Yélamos S, Hegen H, Drulovic J, Téllez-Lara N, Khalil M, Oechtering J, Pérez-Sempere Á, Rodríguez-Antigüedad A, Enrique-Martínez J, Strijbis E, Killestein J, Eichau S, Colombo E, Schaller-Nagengast J, Midaglia L, Sánchez-López AJ, Monreal E, Chan A, Paul F, Rovira À, Tintoré M, Lycke J, Zipp F, Hemmer B, Kuhle J, Montalban X, Comabella M, RIS Study Group. Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome. JAMA Neurol. 2025 Jul 1. PMID: 40455494

Vilaseca A, Vidal-Jordana A, Sceppacuercia S, Calderon W, Arrambide G, Rio J, Tur C, Rodriguez-Acevedo B, Ariño H, Zabalza A, Cobo-Calvo A, Mongay-Ochoa N, Carbonell-Mirabent P, Pappolla A, Carvajal R, Castilló J, Galan I, Midaglia L, Bollo L, Villacieros-Álvarez J, Auger C, Sastre-Garriga J, Tintoré M, Comabella M, Rovira À, Montalban X. Radiologically isolated syndrome: How could we accurately diagnose a subclinical period of multiple sclerosis? Mult Scler. 2025 Jun. PMID: 40443178

Robles-Sánchez MÁ, Amil-Bujan P, Bosch-Farré C, Coll-Martínez C, Arévalo MJ, Anglada-Clofent E, Menéndez-Díaz R, Aroca-Alsina M, Merchan-Ruiz M, Pérez-Hoyos S, Arévalo-Bernabé ÁG, Montalban X, Hernando A, LLufriú S, Peralta-Moncusí S, Brieva L, Ramo-Tello C, Carabí M, Solà-Valls N, Zabay MC, Mañé-Martínez MA, Sastre-Garriga J, Ramió-Torrentà L, Bertran-Noguer C. An expert patient program for people living with multiple sclerosis improves knowledge and empowerment: a pre-test, post-test multicenter implementation study. Front Neurol. 2025. PMID: 40365456

Tur C, Carbonell-Mirabent P, Otero-Romero S, Cobo-Calvo Á, Arévalo MJ, Ariño H, Arrambide G, Auger C, Carvajal R, Castilló J, Comabella M, Galán I, Midaglia L, Nos C, Pappolla A, Pareto D, Río J, Rodríguez-Acevedo B, Saez de Gordoa E, Vidal-Jordana Á, Zabalza A, Sastre-Garriga J, Rovira À, Montalban X, Tintoré M. The Barcelona baseline risk score to predict long-term prognosis after a first demyelinating event: a prospective observational study. Lancet Reg Health Eur. 2025 Jun. PMID: 40291402

Villacieros-Álvarez J, Espejo C, Arrambide G, Dinoto A, Mulero P, Rubio-Flores L, Nieto P, Alcalá C, Meca-Lallana JE, Millan-Pascual J, Martínez-García P, Bernard-Valnet R, González-Suárez I, Orviz A, Téllez R, Navarro Cantó L, Presas-Rodríguez S, Martínez-Yélamos S, Cuello JP, Alonso A, Morales RP, Bravo GÁ, Benyahya L, Trouillet-Assant S, Dyon-Tafan V, Froment Tilikete C, Ruet A, Bourre B, Deschamps R, Papeix C, Maillart E, Kerschen P, Ayrignac X, Rovira À, Auger C, Audoin B, Montalban X, Tintore M, Mariotto S, Cobo-Calvo A, Marignier R. Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurol Neuroimmunol Neuroinflamm. 2025 May. PMID: 40203209

Braga N, Aymerich FX, Alonso J, Mongay-Ochoa N, Pareto D, Montalban X, Vidal-Jordana A, Sastre-Garriga J, Rovira À. Synthetic MRI in Progressive MS: Associations with Disability. AJNR Am J Neuroradiol. 2025 Apr 2. PMID: 40174983

Zabalza A, Thompson A, Rotstein DL, Bar-Or A, Montalban X. Multiple sclerosis and COVID-19: interactions and unresolved issues. Lancet Neurol. 2025 Apr. PMID: 40120619

Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L, De Stefano N. Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Front Immunol. 2025. PMID: 40109340

Carvajal R, Tur C, Borras-Bermejo B, Saylor D, Montalban X, Tintoré M, Otero-Romero S. Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization. Mult Scler. 2025 Jun. PMID: 40071952

Dominguez-Mozo MI, López-Mecández D, Villar LM, Costa-Frossard L, Villarrubia N, Aladro Y, Pilo B, Montalbán X, Comabella M, Casanova-Peño I, González-Suárez I, Martínez-Ginés ML, García-Domínguez JM, García-Calvo E, Machuca-Marcos A, Luque-Garcia JL, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R. Short-chain fatty acids in multiple sclerosis: Associated with disability, number of T2 lesions, and inflammatory profile. Ann Clin Transl Neurol. 2025 Mar. PMID: 40033709

Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L, De Stefano N. Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Front Immunol. 2025. PMID: 39963134

Marignier R, Villacieros-Álvarez J, Espejo C, Arrambide G, Fissolo N, Gutiérrez L, Dinoto A, Mulero P, Rubio-Flores L, Nieto P, Alcalá C, Meca-Lallana JE, Martínez-Garcia P, Millán J, Bernard-Valnet R, González I, Orvíz García A, Tellez R, Navarro L, Presas-Rodríguez S, Romero-Pinel L, Martínez-Yélamos S, Cuello JP, Alonso Torres AM, Piñar R, Álvarez Bravo G, Benyahya L, Trouillet-Assant S, Dyon-Tafani V, Froment Tilikete C, Ruet A, Bourre B, Deschamps R, Papeix C, Maillart E, Kerschen P, Ayrignac X, Rovira A, Auger C, Audoin B, Montalban X, Tintore M, Mariotto S, Cobo-Calvo A. Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study. J Neurol Neurosurg Psychiatry. 2025 Aug 14. PMID: 39939136

Marrodan M, Sao Avilés A, Río J, Cobo-Calvo Á, Fernández V, Pappolla A, Castilló J, Vidal-Jordana Á, Arrambide G, Tur C, Rodríguez-Acevedo B, Zabalza A, Mongay-Ochoa N, Vilaseca A, Rodriguez M, Galán I, Comabella M, Sastre-Garriga J, Tintoré M, Auger C, Rovira À, Montalban X, Midaglia L. Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies. Mult Scler. 2025 Apr. PMID: 39925147

Vilaseca A, Arranz P, Llaurado A, Zabalza A, Fonseca EG, Medina I, Gómez Lorente MA, Alcalá-González L, Borruel N, Fernández-Forcelledo JL, Ariño H, Armangue T, Montalban X, Graus F, Malagelada C. Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction. Neurol Neuroimmunol Neuroinflamm. 2025 Mar. PMID: 39908479

Vilaseca A, Tintoré M, Carbonell-Mirabent P, Rodríguez-Barranco M, Arévalo MJ, Ariño H, Auger C, Bollo L, Carvajal R, Castilló J, Cobo-Calvo A, Comabella M, Fernández V, Galan I, Midaglia L, Mongay-Ochoa N, Nos C, Otero-Romero S, Pappolla A, Rio J, Rodriguez-Acevedo B, Sastre-Garriga J, Sceppacuercia S, Tagliani P, Tur C, Vidal-Jordana A, Villacieros-Álvarez J, Zabalza A, Rovira À, Montalban X, Arrambide G. Uncovering alternative diagnoses in patients with clinical syndromes suggestive of multiple sclerosis: A transversal study from the prospective Barcelona CIS cohort. Mult Scler. 2025 Apr. PMID: 39907218

Cobo-Calvo A, Carbonell-Mirabent P, Tur C, Otero-Romero S, Carvajal R, Arrambide G, Ariño H, Auger C, Villacieros-Álvarez J, Bollo L, Castilló J, Comabella M, Espejo C, Fernández V, Guio-Sánchez C, Galan I, La Puma D, Midaglia LS, Mongay-Ochoa N, Vilaseca A, Arevalo Navines MJ, Nos C, Pappolla A, Rio J, Rodriguez Acevedo B, Zabalza A, Vidal-Jordana A, Pareto D, Sastre-Garriga J, Rovira À, Montalban X, Tintore M. Age-Related Disability Outcomes After a First Demyelinating Event. Neurology. 2025 Feb 25. PMID: 39903901

Dema M, Eixarch H, Hervera A, Castillo M, Villar LM, Montalban X, Espejo C. Disease Aggravation With Age in an Experimental Model of Multiple Sclerosis: Role of Immunosenescence. Aging Cell. 2025 May. PMID: 39894902

Comabella M, Pappolla A, Monreal E, Fissolo N, Sao-Avilés AC, Arrambide G, Carbonell-Mirabent P, Gutierrez L, Cobo-Calvo Á, Tur C, Villacieros-Álvarez J, Vidal-Jordana Á, Castilló J, Galán I, Espiño M, Ariño H, Bollo L, Rodríguez Barranco M, Midaglia LS, Carvajal R, Villarrubia N, Fernández Velasco JI, Rodríguez Acevedo B, Costa Frossard LF, Vilaseca A, Auger C, Zabalza A, Sainz De La Maza S, Mongay-Ochoa N, Río J, Sastre-Garriga J, Rovira À, Tintoré M, Villar LM, Montalban X. Contribution of Blood Biomarkers to Multiple Sclerosis Diagnosis. Neurol Neuroimmunol Neuroinflamm. 2025 Mar. PMID: 39879564

Carvajal R, Guananga-Álvarez D, Tur C, Esperalba J, Rodríguez-Barranco M, Rando-Segura A, Borras-Bermejo B, Cobo-Calvo A, Carbonell-Mirabent P, Zules-Oña R, Rodrigo-Pendas JA, Martínez-Gómez X, Montalban X, Tintore M, Otero-Romero S. Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS. Neurology. 2025 Feb 11. PMID: 39819099

Villacieros-Álvarez J, Espejo C, Arrambide G, Dinoto A, Mulero P, Rubio-Flores L, Nieto P, Alcalá C, Meca-Lallana JE, Millan-Pascual J, Martínez-García P, Bernard-Valnet R, González-Suárez I, Orviz A, Téllez R, Navarro Cantó L, Presas-Rodríguez S, Martínez-Yélamos S, Cuello JP, Alonso A, Piñar Morales R, Álvarez Bravo G, Benyahya L, Trouillet-Assant S, Dyon-Tafan V, Froment Tilikete C, Ruet A, Bourre B, Deschamps R, Papeix C, Maillart E, Kerschen P, Ayrignac X, Rovira À, Auger C, Audoin B, Montalban X, Tintore M, Mariotto S, Cobo-Calvo A, Marignier R. Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurol Neuroimmunol Neuroinflamm. 2025 Mar. PMID: 39752619

Androdias G, Lünemann JD, Maillart E, Amato MP, Audoin B, Bruijstens AL, Bsteh G, Butzkueven H, Ciccarelli O, Cobo-Calvo A, Derfuss T, Di Pauli F, Edan G, Enzinger C, Geraldes R, Granziera C, Hacohen Y, Hartung HP, Hynes S, Inglese M, Kappos L, Kuusisto H, Langer-Gould A, Magyari M, Marignier R, Montalban X, Mycko MP, Nourbakhsh B, Oh J, Oreja-Guevara C, Piehl F, Prosperini L, Sastre-Garriga J, Sellebjerg F, Selmaj K, Siva A, Tallantyre E, van Pesch V, Vukusic S, Weinstock-Guttman B, Zipp F, Tintoré M, Iacobaeus E, Stankoff B. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain. 2025 May 13. PMID: 39707906

Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort. Mult Scler. 2025 Jan. PMID: 39690897

Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, Selmaj K, Patti F, Brieva L, Maidal EM, Alexandri N, Smyk A, Nolting A, Montalban X, Kubala Havrdova E. Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary. Neurodegener Dis Manag. 2024. PMID: 39676554

Mongay-Ochoa N, Pareto D, Alberich M, Carbonell-Mirabent P, Valsasina P, Margoni M, Braga N, Vidal-Jordana A, Auger C, Tintore M, Meani A, Gobbi C, Zecca C, Barkhof F, Schoonheim MM, Strijbis EMM, Gallo A, Bisecco A, Ciccarelli O, De Angelis F, Yiannakas MC, Palace J, Matthews L, Gass A, Eisele P, Lukas C, Bellenberg B, Preziosa P, Montalban X, Rocca MA, Filippi M, Rovira À, Sastre-Garriga J, MAGNIMS study group (Magnetic Resonance Imaging in Multiple Sclerosis). Association of the Cervical Canal Area With Disability and Progression in People With Multiple Sclerosis. Neurology. 2025 Jan 14. PMID: 39666921

Comabella M, Hegen H, Villar LM, Rejdak K, Sao-Avilés A, Behrens M, Sastre-Garriga J, Mongay N, Berek K, Martínez-Yelamos S, Pérez-Miralles F, Abdelhak A, Bachhuber F, Tumani H, Lycke J, Carbonell-Mirabent P, Valls-Carbó A, Rosenstein I, Alvarez-Lafuente R, Castillo-Triviño T, Otaegui D, Llufriu S, Blanco Y, Sánchez-López AJ, García-Merino A, Fissolo N, Gutiérrez L, Villacieros-Álvarez J, Monreal E, Wiendl H, Montalban X, Lünemann JD. Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis. J Neurol. 2024 Dec 12. PMID: 39666032

Villacieros-Álvarez J, Lunemann JD, Sepulveda M, Valls-Carbó A, Dinoto A, Fernández V, Vilaseca A, Castillo M, Arrambide G, Bollo L, Espejo C, Llufriu S, Blanco Y, Armangue T, Álvarez Bravo G, Quiroga-Varela A, Ramió Torrentà L, Cobo-Calvo A, Tintore M, Mariotto S, Montalban X, Comabella M. Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurol Neuroimmunol Neuroinflamm. 2025 Jan. PMID: 39661937

Pinteac R, Soriano J, Matute-Blanch C, Lizcano JM, Duarri A, Malhotra S, Eixarch H, López Comellas G, Montalban X, Comabella M. Chitinase 3-like 1 is neurotoxic in multiple sclerosis patient-derived cortical neurons. Clin Transl Med. 2024 Dec. PMID: 39658520

Brownlee WJ, Vidal-Jordana A, Shatila M, Strijbis E, Schoof L, Killestein J, Barkhof F, Bollo L, Rovira A, Sastre-Garriga J, Tintore M, Rocca MA, Esposito F, Azzimonti M, Filippi M, Bodini B, Lazzarotto A, Stankoff B, Montalban X, Toosy AT, Thompson AJ, Ciccarelli O, MAGNIMS Study Group. Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis. Ann Neurol. 2025 Mar. PMID: 39605172

Chuquisana O, Spatola M, Dinoto A, Sepúlveda M, Mariotto S, Tintore M, Montalban X, Comabella M, Lünemann JD. Soluble TREM2 distinguishes neuromyelitis optica spectrum disorder from MOG antibody disease. Brain. 2025 Feb 3. PMID: 39530260

Carvajal R, Rodríguez-Acevedo B, García-Vasco L, Zabalza A, Ariño H, Bollo L, Cabello-Clotet N, Castilló J, Cobo-Calvo Á, Comabella M, Falcó-Roget A, Galán I, García-Sarreón A, Gómez-Estévez I, Granados G, La Puma D, Mato Chain G, Midaglia L, Nieto-García A, Otero-Romero S, Pappolla A, Rodriguez M, Sansano I, Río J, Tagliani P, Tur C, Vidal-Jordana Á, Vilaseca A, Villar A, Sastre-Garriga J, Oreja-Guevara C, Tintoré M, Montalban X, Arrambide G. Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies. Mult Scler. 2024 Dec. PMID: 39520297

Montalban X, Rodriguez-Acevedo B, Nos C, Resina M, Forner M, Wu Y, Chirieac M. SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis. Ther Adv Neurol Disord. 2024. PMID: 39513023

Portaccio E, Magyari M, Havrdova EK, Ruet A, Brochet B, Scalfari A, Di Filippo M, Tur C, Montalban X, Amato MP. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur. 2024 Sep. PMID: 39444703

Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D, evolutionRMS investigators. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024 Nov. PMID: 39307151

Zabalza A, Pappolla A, Comabella M, Montalban X, Malhotra S. MiRNA-based therapeutic potential in multiple sclerosis. Front Immunol. 2024. PMID: 39267760

Lünemann JD, Sao Avilés A, Tintoré M, Midaglia L, Fissolo N, Gutiérrez L, Wiendl H, Montalban X, Comabella M. Cytomegalovirus immune responses are associated with lower serum NfL and disability accumulation risk at multiple sclerosis onset. Mult Scler. 2024 Oct. PMID: 39246021

Monreal E, Fernández-Velasco JI, Álvarez-Lafuente R, Sainz de la Maza S, García-Sánchez MI, Llufriu S, Casanova B, Comabella M, Martínez-Yélamos S, Galimberti D, Ramió-Torrentà L, Martínez-Ginés ML, Aladro Y, Ayuso L, Martínez-Rodríguez JE, Brieva L, Villarrubia N, Eichau S, Zamora J, Rodero-Romero A, Espiño M, Blanco Y, Saiz A, Montalbán X, Tintoré M, Domínguez-Mozo MI, Cuello JP, Romero-Pinel L, Ghezzi L, Pilo de la Fuente B, Pérez-Miralles F, Quiroga-Varela A, Rubio L, Rodríguez-Jorge F, Chico-García JL, Sainz-Amo R, Masjuan J, Costa-Frossard L, Villar LM. Serum biomarkers at disease onset for personalized therapy in multiple sclerosis. Brain. 2024 Dec 3. PMID: 39101570

Sastre-Garriga J, Vidal-Jordana A, Toosy AT, Enzinger C, Granziera C, Frederiksen J, Ciccarelli O, Filippi M, Montalban X, Tintore M, Pareto D, Rovira À, MAGNIMS Study Group. Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives. Neurology. 2024 Aug 13. PMID: 39018513

Fernández O, Montalbán X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Prieto JM, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A. [XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)]. Rev Neurol. 2024 Jul 16. PMID: 38976584

Zaratin P, Samadzadeh S, Seferoğlu M, Ricigliano V, Dos Santos Silva J, Tunc A, Brichetto G, Coetzee T, Helme A, Khan U, McBurney R, Peryer G, Weiland H, Baneke P, Battaglia MA, Block V, Capezzuto L, Carment L, Cortesi PA, Cutter G, Leocani L, Hartung HP, Hillert J, Hobart J, Immonen K, Kamudoni P, Middleton R, Moghames P, Montalban X, Peeters L, Sormani MP, van Tonder S, White A, Comi G, Vermersch P. The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care - updates at the 2023 plenary event. Front Neurol. 2024. PMID: 38974689

Fernández O, Montalbán X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Prieto JM, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A. [XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)]. Rev Neurol. 2024 Jul 1. PMID: 38934946

Dema M, Eixarch H, Castillo M, Montalban X, Espejo C. IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis. Int J Mol Sci. 2024 Jun 19. PMID: 38928437

Lunemann JD, Hegen H, Villar LM, Rejdak K, Sao-Aviles A, Carbonell-Mirabent P, Sastre-Garriga J, Mongay-Ochoa N, Berek K, Martínez-Yélamos S, Pérez-Miralles F, Abdelhak A, Bachhuber F, Tumani H, Lycke JN, Rosenstein I, Alvarez-Lafuente R, Castillo-Trivino T, Otaegui D, Llufriu S, Blanco Y, Sánchez López AJ, Garcia Merino JA, Fissolo N, Gutierrez L, Villacieros-Álvarez J, Monreal E, Valls-Carbó A, Wiendl H, Montalban X, Comabella M. Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2024 Jul. PMID: 38912898

Collorone S, Coll L, Lorenzi M, Lladó X, Sastre-Garriga J, Tintoré M, Montalban X, Rovira À, Pareto D, Tur C. Artificial intelligence applied to MRI data to tackle key challenges in multiple sclerosis. Mult Scler. 2024 Jun. PMID: 38738527

Kappos L, Edan G, Freedman MS, Hartung HP, Montalbán X, Barkhof F, Koelbach R, MacManus DG, Wicklein EM, BENEFIT and BENEFIT 15 Study Groups. Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial. J Neurol. 2024 Jul. PMID: 38730097

Fox RJ, Cree BAC, de Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Singh CM, Altincatal A, Belviso N, Avila RL, Ho PR, Su R, Engle R, Sangurdekar D, de Moor C, Fisher E, Kieseier BC, Rudick RA. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis. Neurology. 2024 May 14. PMID: 38648580

Carvajal R, Zabalza A, Carbonell-Mirabent P, Martínez-Gómez X, Esperalba J, Pappolla A, Rando A, Cobo-Calvo A, Tur C, Rodriguez M, Río J, Comabella M, Castilló J, Rodrigo-Pendás JÁ, Braga N, Mongay-Ochoa N, Guío-Sánchez C, Vidal-Jordana Á, Arrambide G, Rodríguez-Acevedo B, Midaglia L, Borras-Bermejo B, Galán I, Sastre-Garriga J, Montalban X, Otero-Romero S, Tintoré M. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab. JAMA Netw Open. 2024 Apr 1. PMID: 38607624

Malhotra S, Fissolo N, Rodríguez-Rivera C, Monreal E, Montpeyo M, Urcelay E, Triviño JC, Pérez-García MJ, Segura MF, Pappolla A, Río J, Vilaseca A, Fernández Velasco JI, Miguez A, Goicoechea C, Martinez-Vicente M, Villar LM, Montalban X, Comabella M. Clusterin deficiency is associated with a lack of response to teriflunomide in multiple sclerosis. Clin Transl Med. 2024 Apr. PMID: 38591764

Pappolla A, Auger C, Sao-Aviles A, Tur C, Rodriguez-Barranco M, Cobo-Calvo Á, Mongay-Ochoa N, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Carbonell-Mirabent P, Carvajal R, Castilló-Justribó J, Braga N, Bollo L, Vidal-Jordana A, Arrambide G, Nos C, Salerno A, Galán I, Comabella M, Sastre-Garriga J, Tintoré M, Rovira A, Montalban X, Río J. Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs. Mult Scler. 2024 Jun. PMID: 38551315

Giramé-Rizzo L, de Gordoa ES, Vilaseca A, Auger C, Montalban X. An emerging etiology of spinal cord injury resembling neuromyelitis optica spectrum disorder. Neurol Sci. 2024 Aug. PMID: 38483675

Bollo L, Arrambide G, Cobo-Calvo A, Alvarez JV, Alberich M, Cabello S, Castilló J, Galan I, Midaglia LS, Acevedo BR, Zabalza A, Pappolla A, Mongay Ochoa N, Tintore M, Rio J, Comabella M, Tur C, Auger C, Sastre-Garriga J, Rovira A, Montalban X, Pareto D, Vidal-Jordana A. Trans-Synaptic Degeneration in the Visual Pathway in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurology. 2024 Apr 9. PMID: 38447105

Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS. Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study. Mult Scler. 2024 Apr. PMID: 38436271

Arnold DL, Elliott C, Martin EC, Hyvert Y, Tomic D, Montalban X. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial. Neurology. 2024 Mar 12. PMID: 38335474

Braga N, Pareto D, Mongay-Ochoa N, Rodriguez B, Appriou C, Alberich M, Cabello S, Vidal-Jordana A, Tintore M, Montalban X, Rovira À, Sastre-Garriga J. Optic chiasm manual and automated measurements in sub-acute optic neuritis with OCT and MRI correlations. Eur J Radiol. 2024 Mar. PMID: 38290202

Vidal-Jordana A, Sastre-Garriga J, Tintoré M, Rovira À, Montalban X. Optic nerve topography in multiple sclerosis diagnostic criteria: Existing knowledge and future directions. Mult Scler. 2024 Feb. PMID: 38243584

Oh J, Capezzuto L, Kriara L, Schjodt-Eriksen J, van Beek J, Bernasconi C, Montalban X, Butzkueven H, Kappos L, Giovannoni G, Bove R, Julian L, Baker M, Gossens C, Lindemann M. Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study. Sci Rep. 2024 Jan 2. PMID: 38168498

Vidal-Jordana A, Rovira A, Calderon W, Arrambide G, Castilló J, Moncho D, Rahnama K, Collorone S, Toosy AT, Ciccarelli O, Papadopoulou A, Cerdá-Fuertes N, Lieb JM, Ruggieri S, Tortorella C, Gasperini C, Bisecco A, Capuano R, Gallo A, De Barros A, Salerno A, Auger C, Sastre-Garriga J, Tintore M, Montalban X. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study. Neurology. 2024 Jan 9. PMID: 38165378

Dalla Costa G, Nos C, Zabalza A, Buron M, Magyari M, Sellebjerg F, Guerrero AI, Roselli L, La Porta ML, Martinis M, Bailon R, Kontaxis S, Laporta E, Garcia E, Pokorny FB, Schuller BW, Folarin A, Stewart C, Leocani L, Vairavan S, Cummins N, Dobson R, Hotopf M, Narayan V, Montalban X, Sorensen PS, Comi G. A wearable device perspective on the standard definitions of disability progression in multiple sclerosis. Mult Scler. 2024 Jan. PMID: 38084497

Cagol A, Cortese R, Barakovic M, Schaedelin S, Ruberte E, Absinta M, Barkhof F, Calabrese M, Castellaro M, Ciccarelli O, Cocozza S, De Stefano N, Enzinger C, Filippi M, Jurynczyk M, Maggi P, Mahmoudi N, Messina S, Montalban X, Palace J, Pontillo G, Pröbstel AK, Rocca MA, Ropele S, Rovira À, Schoonheim MM, Sowa P, Strijbis E, Wattjes MP, Sormani MP, Kappos L, Granziera C, MAGNIMS Study Group. Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis. JAMA Neurol. 2024 Feb 1. PMID: 38079177

Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, Selmaj K, Patti F, Brieva L, Maida EM, Alexandri N, Smyk A, Nolting A, Keller B, Montalban X, Kubala Havrdova E. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. Mult Scler. 2023 Dec. PMID: 37978852

Fissolo N, Benkert P, Sastre-Garriga J, Mongay-Ochoa N, Vilaseca-Jolonch A, Llufriu S, Blanco Y, Hegen H, Berek K, Perez-Miralles F, Rejdak K, Villar LM, Monreal E, Alvarez-Lafuente R, Soylu OK, Abdelhak A, Bachhuber F, Tumani H, Martínez-Yélamos S, Sánchez-López AJ, García-Merino A, Gutiérrez L, Castillo-Trivino T, Lycke J, Rosenstein I, Furlan R, Filippi M, Téllez N, Ramió-Torrentà L, Lünemann JD, Wiendl H, Eichau S, Khalil M, Kuhle J, Montalban X, Comabella M. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2024 Apr 12. PMID: 37940409

Kappos L, Traboulsee A, Li DKB, Bar-Or A, Barkhof F, Montalban X, Leppert D, Baldinotti A, Schneble HM, Koendgen H, Sauter A, Wang Q, Hauser SL. Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. J Neurol. 2024 Feb. PMID: 37906326

Domínguez-Mozo MI, González-Suárez I, Villar LM, Costa-Frossard L, Villarrubia N, Aladro Y, Pilo B, Montalbán X, Comabella M, Casanova-Peño I, Martínez-Ginés ML, García-Domínguez JM, García-Martínez MÁ, Arroyo R, Álvarez-Lafuente R. Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response. Front Immunol. 2023. PMID: 37841253

Sotirchos ES, Hu C, Smith MD, Lord HN, DuVal AL, Arrambide G, Montalban X, Akgün K, Ziemssen T, Naismith RT, Hersh CM, Hyland M, Krupp LB, Nicholas JA, Bermel RA, Mowry EM, Calabresi PA, Fitzgerald KC. Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis. Neurology. 2023 Dec 4. PMID: 37816633

Coll L, Pareto D, Carbonell-Mirabent P, Cobo-Calvo Á, Arrambide G, Vidal-Jordana Á, Comabella M, Castilló J, Rodrı Guez-Acevedo B, Zabalza A, Galán I, Midaglia L, Nos C, Auger C, Alberich M, Río J, Sastre-Garriga J, Oliver A, Montalban X, Rovira À, Tintoré M, Lladó X, Tur C. Global and Regional Deep Learning Models for Multiple Sclerosis Stratification From MRI. J Magn Reson Imaging. 2024 Jul. PMID: 37803817

Graves JS, Elantkowski M, Zhang YP, Dondelinger F, Lipsmeier F, Bernasconi C, Montalban X, Midaglia L, Lindemann M. Assessment of Upper Extremity Function in Multiple Sclerosis: Feasibility of a Digital Pinching Test. JMIR Form Res. 2023 Oct 2. PMID: 37782540

Ruggieri S, Prosperini L, Al-Araji S, Annovazzi PO, Bisecco A, Ciccarelli O, De Stefano N, Filippi M, Fleischer V, Evangelou N, Enzinger C, Gallo A, Garjani A, Groppa S, Haggiag S, Khalil M, Lucchini M, Mirabella M, Montalban X, Pozzilli C, Preziosa P, Río J, Rocca MA, Rovira A, Stromillo ML, Zaffaroni M, Tortorella C, Gasperini C, MAGNIMS Study Group. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study. J Neurol Neurosurg Psychiatry. 2024 Jan 11. PMID: 37775266

Midaglia L, Rovira A, Miró B, Río J, Fissolo N, Castilló J, Sánchez A, Montalban X, Comabella M. Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients. Eur J Neurol. 2024 Jan. PMID: 37754568

Coles AJ, Achiron A, Traboulsee A, Singer BA, Pozzilli C, Oreja-Guevara C, Giovannoni G, Comi G, Freedman MS, Ziemssen T, Shiota D, Rawlings AM, Wong AT, Chirieac M, Montalban X. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study. Ther Adv Neurol Disord. 2023. PMID: 37745914

Carvajal R, Tur C, Martínez-Gómez X, Bollo L, Esperalba J, Rodriguez M, Pappolla A, Cobo-Calvo A, Carbonell P, Borras-Bemejo B, Río J, Castilló J, Braga N, Mongay-Ochoa N, Rodrigo-Pendás JÁ, Vidal-Jordana Á, Arrambide G, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Galán I, Comabella M, Sastre-Garriga J, Montalban X, Tintoré M, Otero-Romero S. A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients. Mult Scler. 2023 Dec. PMID: 37728389

Villacieros-Álvarez J, Espejo C, Arrambide G, Castillo M, Carbonell-Mirabent P, Rodriguez M, Bollo L, Castilló J, Comabella M, Galán I, Midaglia L, Mongay-Ochoa N, Nos C, Rio J, Rodríguez-Acevedo B, Sastre-Garriga J, Tur C, Vidal-Jordana A, Vilaseca A, Zabalza A, Auger C, Rovira A, Montalban X, Tintoré M, Cobo-Calvo Á. Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis. Ann Neurol. 2023 Sep 14. PMID: 37705507

Wilson D, Chan D, Chang L, Mathis R, Verberk I, Montalban X, Comabella M, Fissolo N, Bielekova B, Masvekar R, Chitnis T, Ziemssen T, Akgün K, Blennow K, Zetterberg H, Brück W, Giovannoni G, Gnanapavan S, Bittner S, Zipp F, Comi G, Furlan R, Lehmann S, Thebault S, Freedman M, Bar-Or A, Kramer M, Otto M, Halbgebauer S, Hrusovsky K, Plavina T, Khalil M, Piehl F, Wiendl H, Kappos L, Maceski A, Willemse E, Leppert D, Teunissen C, Kuhle J. Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury. Clin Chem Lab Med. 2024 Jan 26. PMID: 37702323

Marzo B, Vidal-Jordana A, Castilló J, Robles-Sanchez MA, Otero-Romero S, Tintore M, Montalban X, Buti M, Riveiro-Barciela M. Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study. J Neurol. 2024 Jan. PMID: 37695530